Outlook Therapeutics (NASDAQ:OTLK) Posts Earnings Results, Misses Estimates By $0.03 EPS

Outlook Therapeutics (NASDAQ:OTLK – Get Rating) posted its quarterly earnings results on Friday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), MarketWatch Earnings reports.

Outlook Therapeutics stock opened at $1.60 on Friday. Outlook Therapeutics has a one year low of $1.19 and a one year high of $3.27. The business has a fifty day moving average price of $1.78 and a 200-day moving average price of $1.61. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.20.

In other Outlook Therapeutics news, Director Kurt J. Hilzinger acquired 95,597 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The stock was bought at an average price of $1.49 per share, with a total value of $142,439.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt J. Hilzinger acquired 41,160 shares of the company’s stock in a transaction that occurred on Thursday, February 24th. The shares were acquired at an average cost of $1.46 per share, with a total value of $60,093.60. The disclosure for this purchase can be found here. Insiders bought 142,757 shares of company stock valued at $212,133 over the last ninety days. Corporate insiders own 2.30% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Invesco Ltd. boosted its stake in Outlook Therapeutics by 33.6% during the third quarter. Invesco Ltd. now owns 31,332 shares of the company’s stock valued at $68,000 after buying an additional 7,876 shares during the period. American International Group Inc. lifted its stake in Outlook Therapeutics by 19.5% during the first quarter. American International Group Inc. now owns 56,554 shares of the company’s stock worth $101,000 after purchasing an additional 9,225 shares during the last quarter. Deutsche Bank AG lifted its stake in Outlook Therapeutics by 20.6% during the fourth quarter. Deutsche Bank AG now owns 61,794 shares of the company’s stock worth $84,000 after purchasing an additional 10,565 shares during the last quarter. Citigroup Inc. lifted its stake in Outlook Therapeutics by 100.5% during the fourth quarter. Citigroup Inc. now owns 22,943 shares of the company’s stock worth $31,000 after purchasing an additional 11,498 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Outlook Therapeutics by 375.5% during the third quarter. BNP Paribas Arbitrage SA now owns 16,039 shares of the company’s stock worth $35,000 after purchasing an additional 12,666 shares during the last quarter. 11.71% of the stock is owned by institutional investors.

Outlook Therapeutics Company Profile (Get Rating)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Featured Articles